Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab.

Garcia P, Ortiz MJ, Duran G, Falco E, Munoz A, Garcia-Paredes B, Salgado M, Lopez-Ladron A, Vieitez de Prado JM, Valladares M, Salud A, Guillen-Ponce C, Lopez R, Robles L, Juarez A, Serrano S, Montagut C, Zanui M, Gil Raga M, La Casta A, Benavides M, Aranda E.

Ann. Oncol. 2015; 26. FI: 7.040 (Q1).

Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry.

Romero I, Churruca CM, Redondo A, Santaballa A, Calvo E, Ojeda B, Del Campo JM, Lainez N, Garcia-Martinez E, Romeo M, Bover I, Mendiola C, Caballero C, Martinez J, Herrero A, Sanchez AB, De Juan A, Hernando S, Lopez-Guerrero JA, Poveda A, GEICO.

J. Clin. Oncol. 2015; 33. FI: 18.428 (Q1).

Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?.

Ciria JP, Eguiguren M, Cafiero S, Uranga I, Diaz de Cerio I, Querejeta A, Urraca JM, Minguez J, Guimon E, Puertolas JR.

Rep Pract Oncol Radiother. 2015; 20: 1-11. FI: 0.000 (Q0).

Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study.

Vera R, Gomez ML, Ayuso JR, Figueras J, Garcia P, Martinez-Marin V, La Casta A, Ruiz A, Safont MJ, Aparicio J, Campos JM, Camara JC, Martin-Richard M, Montagut C, Pericay C, Vieitez de Prado JM, Falco E, Jorge M, Marin M, Salgado M, GEMCAD.

J. Clin. Oncol. 2015; 33. FI: 18.428 (Q1).

Aptamers Overview: Selection, Features and Applications.

Hernandez LI, Machado I, Schaefer T, Hernandez FJ.

Curr. Top. Med. Chem. 2015; 15: 1066-1081. FI: 3.402 (Q1).

Written in Blood: Kissing Disease miRNAs Could Predict Outcome of Patients With Chronic Lymphocytic Leukaemia.

Lawrie CH.

Ebiomedicine. 2015; 2: 489-490. FI: 0.000 (Q0).

A reddish nodule on the nose.

del Alcazar E, Gutierrez MP, Lobo C, Tuneu A.

Int. J. Dermatol. 2015; 54: 19-20. FI: 1.312 (Q3).

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.

Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg, JD, Perales MA.

Leuk. Lymphoma. 2015; 56: 663-670. FI: 2.891 (Q2).

Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.

Ceberio I, Dai K, Devlin SM, Barker JN, Castro-Malaspina H, Goldberg JD, Giralt S, Adel NG, Perales MA.

Bone Marrow Transplant. 2015; 50: 438-443. FI: 3.570 (Q2).

Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation.

Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat, U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA.

Biol. Blood Marrow Transplant. 2015; 21: 971-983. FI: 3.404 (Q2).